The present invention relates to Adelmidrol for use in the treatment of diseases characterized by insufficient specific agonism of the PPAR-gamma receptor in humans or animals, more particularly in the treatment of articular chondropathies of mechanical, toxic, iatrogenic, degenerative origin, or associated with inflammatory phenomena mainly related to organs and tissues not belonging to the osteoarticular system； fibrogenesis of the articular cartilages； chronic inflammatory bowel diseases (IBDs) such as Crohn's disease and ulcerative colitis； Irritable Bowel Syndrome (IBS)； diseases characterized by an abnormal fibrosis of the connective tissue, such as systemic sclerosis, particularly of the skin and lung； eye disorders characterized by angiogenesis, fibrosis, inflammation and oxidative stress.
